Clinical Trial Detail

NCT ID NCT02761057
Title Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

papillary renal cell carcinoma

Therapies

Savolitinib

Cabozantinib

Crizotinib

Sunitinib

Age Groups: senior adult child

No variant requirements are available.